Company intelligence / Profile preview

Gang Biopharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Gang Biopharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative therapies for oncology and other high-unmet-need therapeutic areas. The company leverages its internal R&D capabilities to advance a pipeline of small molecule inhibitors and biologics targeting validated pathways such as EGFR and PD-1. Gang Biopharmaceutical aims to provide cost-effective and high-quality treatment options for patients primarily in the Chinese market while exploring global development opportunities. Their lead programs are currently in mid-stage clinical trials for various solid tumor indications.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Gang Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gang Biopharmaceutical.

Explore the full profile